Can JAK Inhibitors Save Lives From COVID-19? Pfizer Might Let RECOVERY Answer The Question
Promising Signs From Phase II Study
Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.
